CompanyTrack
Sign Up Log In
C

CALDAN THERAPEUTICS LIMITED

Dissolved Kilmacolm

Research and experimental development on biotechnology

0 employees Website
Research and experimental development on biotechnology
C

CALDAN THERAPEUTICS LIMITED

Research and experimental development on biotechnology

Founded 14 Sept 2015 Dissolved Kilmacolm, United Kingdom 0 employees caldantherapeutics.com
Research and experimental development on biotechnology
Accounts Submitted 9 Jan 2024
Confirmation Statement Submitted 12 Jun 2024
Net assets £-2.92M £1.02M 2023 year on year
Total assets £736.05K £634.98K 2023 year on year
Total Liabilities £3.66M £383.88K 2023 year on year
Charges 2
2 satisfied

AI Analysis

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

7 St James Terrace Lochwinnoch Road Kilmacolm PA13 4HB

Office (Edinburgh)

7-11 Melville St, Edinburgh EH3 7PE

Telephone

0770 106 7727

Credit Report

Discover CALDAN THERAPEUTICS LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Financials

Period 1 Jan → 31 Dec 2023
Type Total Exemption Full
Next accounts 31 December 2024
Due by 30 September 2025 9 months

Net Assets, Total Assets & Total Liabilities (2022–2023)

Cash in Bank

£626.92k

Decreased by £596.29k (-49%)

Net Assets

-£2.92M

Decreased by £1.02M (-53%)

Total Liabilities

£3.66M

Increased by £383.88k (+12%)

Turnover

N/A

Employees

N/A

Debt Ratio

497%

Increased by 258 (+108%)
See 10 Year Full Financials

Financial History

Revenue, profit, EBITDA and key financial figures

2023
Dec Year End
2022
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

4 Allotments 466,210 Shares £466.21 Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
18 Jan 202377,713£77.713£0.001
11 Jan 2023166,610£166.61£0.001
10 May 202268,883£68.883£0.001
5 Oct 2017153,004£153.004£0.001

Officers

Officers

5 active 6 resigned
Status
Graeme MilliganDirectorBritishScotland6914 Sept 2015Active
Lori Krim GoughDirectorAmericanUnited States5115 Nov 2023Active
Mark Anthony PaytonDirectorBritishEngland7231 Jul 2019Active
Mary Eugenie CanningDirectorIrishUnited Kingdom5122 Apr 2021Active
Trond UlvenDirectorNorwegianDenmark5514 Sept 2015Active

Shareholders

Shareholders (15)

Scottish Enterprise
18.6%
1,518,77114 Jun 2023
Trond Ulven
2.4%
200,00014 Jun 2023
Stephen Connolly
0.8%
68,88314 Jun 2023

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Epidarex Capital Ii Lp

United Kingdom

Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 25 To 50 Percent As Firm
  • Voting Rights 25 To 50 Percent As Firm

Scottish Enterprise

Ceased 6 Apr 2016

Ceased

Epidarex Capital Partners Limited

Ceased 6 Apr 2016

Ceased
See All Controllers

Group Structure

Group Structure

EPIDAREX CAPITAL II, LP united kingdom significant influence or control
EPIDAREX MANAGEMENT LTD united kingdom
ELI LILLY AND COMPANY LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors as firm, significant influence or control as firm
EPIDAREX CAPITAL UK GP, LLP united kingdom voting rights 25 to 50 percent limited liability partnership, right to share surplus assets 25 to 50 percent limited liability partnership
ELI LILLY GROUP LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors as firm, significant influence or control as firm
EPIDAREX CAPITAL PARTNERS LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors
EPIDAREX PARTNERS LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors
ELI LILLY AND COMPANY united states of america
CALDAN THERAPEUTICS LIMITED Current Company

Charges

Charges

2 satisfied

Documents

Company Filings

DateCategoryDescriptionDocument
26 Feb 2025MortgageMortgage Satisfy Charge FullView(1 page)
7 Nov 2024AddressChange Registered Office Address Company With Date Old Address New AddressView(3 pages)
1 Oct 2024ResolutionResolutionsView(1 page)
12 Jun 2024Confirmation StatementConfirmation statement made on 2024-06-12 with updatesView(8 pages)
9 Jan 2024AccountsAnnual accounts made up to 2023-09-30View(28 pages)
26 Feb 2025 Mortgage

Mortgage Satisfy Charge Full

View Document(1 page)
7 Nov 2024 Address

Change Registered Office Address Company With Date Old Address New Address

View Document(3 pages)
1 Oct 2024 Resolution

Resolutions

View Document(1 page)
12 Jun 2024 Confirmation Statement

Confirmation statement made on 2024-06-12 with updates

View Document(8 pages)
9 Jan 2024 Accounts

Annual accounts made up to 2023-09-30

View Document(28 pages)

Recent Activity

Latest Activity

Mortgage Satisfy Charge Full

11 months ago on 26 Feb 2025

Change Registered Office Address Company With Date Old Address New Address

1 years ago on 7 Nov 2024

Resolutions

1 years ago on 1 Oct 2024

Confirmation statement made on 2024-06-12 with updates

1 years ago on 12 Jun 2024

Annual accounts made up to 2023-09-30

2 years ago on 9 Jan 2024